Buying Pluri stock in 2026: price, results and vigilance

Are you looking to buy Pluri stock? This NASDAQ ticker designates Pluri, an Israeli company that moved from biometric cybersecurity (Plurilock) to a biotech pivot: a platform of cell therapies and investments in cells. A micro-cap in complete mutation, in structural losses. This sheet gathers the price, verified results, the dividend situation and the method for buying from France.

Pluri stock price

The stock is quoted by your broker or on the reference financial platforms, under the code PLUR on the NASDAQ; the American session hours are detailed below.

Pluri stock profile

CompanyPluri Inc. (formerly Plurilock Security Solutions)
MarketNASDAQ (New York) — biotechnology micro-capitalisation
Ticker / SymbolPLUR
ISINUS72942G2030
HeadquartersIsrael (originally Haifa)
SectorBiotechnology: cell-therapy technologies and related investments
Quotation currencyUS dollar (USD)
Fiscal year end30 June
PEA eligibilityNo (issuer domiciled outside the EU/EEA)

Pluri presentation: the strategic pivot

From cybersecurity to biotech

Pluri used to be Plurilock: a Canadian-Israeli behavioural biometric-security company, listed with tiny revenues and chronic losses. After a change of control and strategy, the company became Pluri: a biotech vehicle backed by cell-therapy technologies — cell culture and expansion for therapeutic use — inherited from Israeli assets; check the company’s latest published reports for the exact perimeter of its current strategy.

The profile of a micro-cap in mutation

The accounts tell a story under construction: residual revenues of around $1 million per year, losses above $20 million annually financed through capital raises, and a valuation that depends on strategic and clinical announcements. On this type of file, the analysis boils down to three questions: what real perimeter, what remaining cash, what plan for profitability; official releases are the only valid basis.

A governance to watch closely

Rapid identity changes — name, sector, country of activity — are typical of pivoting micro-caps: they require systematically checking the latest official document before any decision, because old information no longer describes the current company. Checking the ISIN (US72942G2030) remains the fundamental reflex; our guides on the stock market detail these checks.

Pluri results and financial data

Consolidated accounts of the last three fiscal years ended 30 June:

IndicatorEnded June 2024Ended June 2025Ended June 2026One-year change
Revenue$1.34m$1.02m$1.02mstable
Net income-$22.6m-$23.8m-$23.8mloss

Amounts in millions of dollars. Source: consolidated accounts via StockAnalysis; data consulted on 07/11/2026.

The table describes a company in transition: stable but tiny residual revenues, and structural losses of around $24 million per year — the cost of the biotech pivot and of the group structure. Viability depends entirely on the cash from capital raises and on the materialisation of the new strategy; check the latest published reports for these elements.

Pluri stock dividend

Pluri pays no dividend: in losses and in full mutation, resources are kept to finance the strategy; the shareholder’s return depends exclusively on the stock’s valuation; check the latest published reports.

Should You Buy Pluri Stock?

Strengths:

  • A documented biotech pivot on a cell-therapy platform.
  • Micro-capitalisation: large swings possible on strategic announcements.
  • Cash from recent raises, buying execution time.
  • Exposure to the cell-therapy theme, in long-term growth.

Points to watch:

  • Near-zero revenues and massive structural losses relative to the scale.
  • Recent strategic identity, still under construction: systematic documentary follow-up.
  • Permanent dilution risk through capital raises.
  • Stock outside the PEA: held in an ordinary securities account.

Pluri belongs to the bets on mutating micro-caps: a tiny, assumed fraction of the portfolio, never a core position; the selection discipline is described in our pages on the best stocks.

Fundamental and technical analysis of Pluri stock

Fundamental analysis

The follow-up focuses on three signals: the real biotech perimeter (assets, programmes, partnerships), the remaining cash and its consumption rate, and the pivot’s governance. Official releases publish these elements; consult the latest reports before any decision.

Technical analysis

On a mutating micro-cap, the chart is dominated by announcements: the NASDAQ trades from 3:30 pm to 10:00 pm Paris time; supports and moving averages apply with extreme caution; our trading guides detail position-sizing discipline on this type of stock.

How to buy Pluri stock from France?

  1. Choose a broker giving access to the NASDAQ — compare fees in our selection of the best stock brokers.
  2. Open an ordinary securities account (stock outside the PEA); our guides explain how to buy stocks from France.
  3. Verify the line: ticker PLUR, ISIN US72942G2030.
  4. Place a limit order during the American session, with a minimal size.
  5. Follow the strategy and the cash; consult the company’s latest published reports.

Taxation

Capital gains fall under the 30% single flat levy on an ordinary securities account; no dividend being paid, taxation is limited to sales; the W-8BEN form applies to your American lines. (Non-French readers: check your own jurisdiction’s rules.)

Frequently asked questions about Pluri stock

Is Pluri the former Plurilock?

Yes: the company listed under PLUR is the heir of Plurilock Security Solutions, renamed Pluri after its pivot from cyber to cell-therapy technologies; its current ISIN is US72942G2030.

What are Pluri’s latest results?

Residual revenue of around $1.02 million (stable) and a net loss of around $23.8 million for the fiscal year ended June 2026, according to the accounts consulted on StockAnalysis on 07/11/2026.

Does Pluri pay a dividend?

No: no distribution; resources finance the new strategy; the return depends on the price.

Can this stock go in a PEA?

No: the issuer is domiciled outside the EU/EEA; the line is held in an ordinary securities account.

What is the file’s main risk?

The combination of a recent strategic pivot, near-zero revenues and a large annual cash consumption: viability depends on capital raises and on the biotech strategy materialising.

Disclaimer: this content is informational and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not indicative of future performance.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Pluri: profile and business model

Pluri is a listed company whose stock is bought through an online broker. Before any decision, verify the updated information — exact sector, capitalisation, listing venue and ticker code — in the issuer’s latest regulated news: these elements change (spin-offs, renamings, index changes).

How to buy Pluri stock: the complete method

  1. Open a securities account (or a PEA if the stock is eligible) with a regulated broker;
  2. Search for the Pluri stock on the listing venue indicated by the issuer;
  3. Place a limit order — essential on an illiquid stock: a market order can execute very far from the last displayed price;
  4. Size the position: maximum 2-5% of the portfolio per line, with your written investment thesis (why I buy, when I sell).

For the complete selection method before buying: how to buy stocks and our PEA dossier for eligible stocks.

Sector analysis and positioning

Every stock sits in a sector with its own cycles: technology and healthcare reward growth, finance and energy reward dividends, industry depends on order books. Three questions to place a company in its sector: what is its durable competitive advantage (brand, patent, network, cost)? What market share does it hold and in which direction is it moving? Is the sector in structural growth or decline? A solid company in a declining sector remains a risky investment; an average company in a growing sector can outperform. Always combine this reading with the cycle position: cyclical stocks (automotive, luxury, materials) offer the best opportunities early in the cycle and the worst at the end of it.

Dividends and shareholder policy

A dividend is a cash flow paid to shareholders, decided at the general meeting on the board’s proposal. Three indicators to assess it: the yield (annual dividend / share price); the payout ratio (the share of net profit paid out — beyond 80%, sustainability becomes doubtful); and regularity (a dividend cut almost always signals trouble). Beware of abnormally high yields (>10%): the market usually anticipates an upcoming reduction. To go further: our dividends dossier.

Strengths, risks and points to watch

Strengths to document: market position, recurring cash-flow generation, controlled indebtedness (net debt / EBITDA below 2-3 depending on the sector), quality of management. Risks to monitor: customer or geographic concentration, technological dependence, exposure to exchange rates, ongoing litigation, family governance or a dominant controlling shareholder. The good practice: write the investment thesis in three lines (why I buy, what would validate the thesis, what would invalidate it) and reread it at every earnings release.

Classic mistakes of the retail investor

Behavioural studies consistently document the same costly biases. Anchoring: clinging to your purchase price as a reference (« I’ll sell when I get back to my level ») while the market completely ignores that price. Loss aversion: selling winners too quickly and keeping losers too long — the opposite of rational discipline. Confirmation bias: reading only the analyses that confirm the position already held. Herding: buying what everyone is talking about, often at the worst moment. The antidote comes down to three practices: a written thesis at purchase (reread at every earnings release), selling rules defined before becoming emotional, and an error journal where every failed decision is recorded with its real cause — not the convenient one.

Taxation and wrappers: PEA or securities account (France)

The following applies to investors taxed in France, the site’s home market. Two wrappers exist there for holding stocks. The PEA: a ceiling of €150,000 in payments, eligibility limited to European stocks, but after 5 years of holding, capital gains are exempt from income tax (only the 17.2% social levies remain due); dividends compound tax-free as long as they are not withdrawn. The ordinary securities account: no payment limit, access to all world markets, but taxation on every flow (30% flat tax on capital gains and dividends, or the progressive scale with a holding-period allowance for securities acquired before 2018). For European stocks held long, the PEA wins; for global diversification (United States, Asia), the securities account is the natural choice. UK readers hold equivalents such as the ISA or SIPP; US readers have Roth or traditional brokerage retirement accounts — check the rules of your own jurisdiction before choosing a wrapper.

FAQ

What minimum budget to start investing in stocks?

Most online brokers accept first payments of 50 to 100 €. What matters is not the initial amount but regularity: scheduled monthly payments (DCA) smooth out timing risk.

Should you buy all at once or spread purchases?

Spreading purchases (DCA) reduces the risk of buying at the top; a one-off purchase maximises return if the market then rises. Over long horizons, documented studies show a slight edge for lump-sum buying, but spreading dominates psychologically for a beginner.

How to limit the risk of loss?

Three levers: diversification (at least 15-20 lines or one broad ETF), position sizing (no single line above 5% of the portfolio) and horizon (the longer it is, the more bad-timing risk falls).

Where to follow the price and news of a stock?

Real-time quotes are available on the issuer’s website, broker platforms and financial news feeds; shareholders receive regulated press releases by email after registering with the issuer.

Glossary: the terms to know

  • Market capitalisation: price × number of shares; a company’s « size » on the market.
  • P/E (price earnings ratio): price / earnings per share; how many years of profit you are paying for. Below 15: a cautious market or neglected stocks; above 25: strong growth expectations.
  • Earnings per share (EPS): net profit / number of shares; the basis of the P/E calculation.
  • Dividend yield: annual dividend / price; to compare with the money-market rate and government bonds.
  • Free cash flow: cash generated after investments; the real source of dividends and buybacks.
  • Net debt / EBITDA: indebtedness indicator; beyond 3-4 depending on the sector, room for manoeuvre narrows.
  • Limit order: an order with a maximum buy price (or minimum sell price) set in advance; indispensable protection on illiquid stocks.
  • Spread: the gap between buy and sell prices; on small caps it can cost more than the commission.
  • Risk premium: the extra return demanded for holding a stock rather than a risk-free asset.
  • Volatility: the amplitude of swings; it measures short-term risk, not company quality.
  • Beta: a stock’s sensitivity to the market; beta above 1 = amplifies index moves, below 1 = dampens them.
  • Free float: the share of capital actually tradable on the market; a low float makes the price more volatile.
  • Share buyback: the company repurchases its own shares; a cash-return mechanism that supports earnings per share.
  • Adjusted earnings: profit restated for exceptional items as presented by the company; take it with perspective, the definition varies from one issuer to another.

Informational content, not investment advice. Past performance does not predict future performance; investing in stocks carries a risk of capital loss.

Suivez-nous sur Telegram